IVF Live Birth Rates at 35, 38, and 41: The Cumulative Success Calculation That Determines Whether a Second Cycle Is Worth $28K
IVF Live Birth Rates at 35, 38, and 41: The Cumulative Success Calculation That Determines Whether a Second Cycle Is Worth $28K
You just got a consultation packet from a clinic boasting a "55% success rate." That number is on the brochure, in the welcome email, probably on a tasteful graphic on their waiting room wall. What it almost certainly does not tell you: whether that's per egg retrieval or per embryo transfer, how it breaks down by your age, whether they exclude poor-prognosis patients, or what happens to your odds if the first cycle fails.
This is the number that will shape a $28K–$84K financial decision. And right now, most patients are comparing it the same way you'd compare mortgages if every lender used a different definition of "interest rate."
Here's how to actually read the data — and what cumulative success math looks like for real people at 35, 38, and 41.
The Stat That's Never What It Seems
When a clinic says "55% success rate," they mean one of several possible things:
- Clinical pregnancy rate per transfer (most commonly cited — and the most optimistic)
- Live birth rate per transfer (what actually matters)
- Live birth rate per retrieval (more conservative — accounts for cycles that never reach transfer)
- Live birth rate using own eggs only (excludes donor egg cycles, which have higher rates)
The difference between these isn't cosmetic. A clinic might have a 55% clinical pregnancy rate per transfer but only a 38% live birth rate per retrieval for patients your age — because not every retrieval yields transferable embryos, and not every clinical pregnancy becomes a baby.
SART (the Society for Assisted Reproductive Technology) publishes data that breaks this down, but as we've written about in IVF Live Birth Rates at 35, 38, and 41: How to Read SART Clinic Data Before Committing to a $25K Cycle, the tables are dense and the denominators shift in ways that are easy to miss unless you've spent time in them.
The number that actually determines your financial planning isn't the per-transfer success rate. It's the cumulative live birth probability across the number of cycles you can realistically afford.
The Age-Based Baseline: What SART Data Actually Shows
Using SART 2022 national data for patients using their own eggs (the most recently validated reporting cycle), here are the approximate live birth rates per intended egg retrieval:
| Age | Live Birth Rate per Retrieval | Notes |
|---|---|---|
| Under 35 | ~44–48% | Highest embryo quality, most eggs retrieved |
| 35–37 | ~38–42% | Modest decline begins |
| 38–40 | ~26–31% | Meaningful drop; PGT-A often recommended |
| 41–42 | ~14–18% | Significant decline; donor egg conversation common |
| Over 42 | ~6–10% | Most clinics recommend donor eggs at this stage |
These are national averages. Individual clinics vary by 10–15 percentage points around these figures — and whether that variation represents genuine clinical excellence or patient selection is the question every clinic comparison needs to answer.
This is exactly the kind of analysis Feralyx runs for you — comparing clinic-level SART outcomes against the national baseline for your specific age and diagnosis, so you're not eyeballing a brochure number.
The Cumulative Math: What Your Real Odds Look Like Across 2–3 Cycles
This is the calculation most patients never see — and it fundamentally changes how you should think about cost.
Cumulative probability of at least one live birth across multiple independent cycles:
Formula: 1 minus (1 minus per-cycle rate) raised to the number of cycles
At age 35 (45% per cycle):
- 1 cycle: 45%
- 2 cycles: 1 - (0.55 × 0.55) = 69.8%
- 3 cycles: 1 - (0.55 × 0.55 × 0.55) = 83.4%
At age 38 (28% per cycle):
- 1 cycle: 28%
- 2 cycles: 1 - (0.72 × 0.72) = 48.2%
- 3 cycles: 1 - (0.72 × 0.72 × 0.72) = 62.7%
At age 41 (16% per cycle):
- 1 cycle: 16%
- 2 cycles: 1 - (0.84 × 0.84) = 29.4%
- 3 cycles: 1 - (0.84 × 0.84 × 0.84) = 40.7%
Now pair those probabilities with realistic all-in costs (retrieval + meds + monitoring + PGT-A + FET), which as we break down in IVF Total Cost in 2026: Why a $15K Clinic Quote Becomes $28K–$35K After Meds, PGT, and the FET You'll Probably Need, run $28K–$35K per cycle at most U.S. clinics:
| Age | Cycles | Cumulative Success | Estimated Total Cost |
|---|---|---|---|
| 35 | 1 | 45% | ~$28K |
| 35 | 2 | 70% | ~$56K |
| 35 | 3 | 83% | ~$84K |
| 38 | 1 | 28% | ~$28K |
| 38 | 2 | 48% | ~$56K |
| 38 | 3 | 63% | ~$84K |
| 41 | 1 | 16% | ~$30K |
| 41 | 2 | 29% | ~$60K |
| 41 | 3 | 41% | ~$90K |
Note: Per-cycle costs increase slightly at 41+ due to higher medication requirements. PGT-A adds $3K–$6K per retrieval and is typically recommended at 38+.
The takeaway here isn't discouraging — it's that the decision calculus is completely different at 35 versus 41. For a 35-year-old, three cycles gets you to 83% cumulative odds. For a 41-year-old, three cycles still leaves you below 50%. That's not a reason to stop — it may be a reason to have a very different conversation with your clinic about protocol, donor options, or both.
You can model this for your specific age, diagnosis, and clinic's published rates at Feralyx.
Why Clinics Don't Show You This Math — And What to Look For Instead
Here's something worth knowing about how fertility medicine markets itself. A 2024 analysis of SART-reporting clinics found meaningful variation in how clinics handle patients who are poor responders. Some clinics convert a retrieved cycle to a freeze-all or cancel it before transfer — and how they count (or don't count) those cycles in their reported success rates varies.
A clinic with a 52% live birth rate per transfer but a 30% cancellation rate before transfer is not the same as a clinic with a 44% live birth rate per transfer and a 12% cancellation rate. The first clinic looks better on the stat sheet. But if you're the patient whose cycle gets cancelled, you've spent $15K–$18K on a retrieval that doesn't show up in their "success" denominator.
This dynamic isn't unique to fertility. A recent KFF Health News investigation into infant formula competition inside NICUs documented how Abbott and Mead Johnson used marketing, exclusivity contracts, and carefully framed outcome data to compete for hospital relationships — rather than on raw clinical evidence. Fertility clinics face similar incentive structures: the patients who make a clinic look good are the ones most likely to succeed regardless of where they go. Turning away harder cases is a rational business strategy that looks indistinguishable from clinical excellence in the aggregate stat.
The question to ask every clinic is not "what is your success rate?" It's: "What is your live birth rate per intended retrieval, for patients my age, and what percentage of retrievals are cancelled before reaching transfer?"
The Insurance Risk Layer Nobody Talks About
Here's a scenario that happens more often than it should: you start a cycle, the retrieval goes well, you have embryos waiting for FET, and then your insurance situation changes. A policy lapse. An employer switch. A prior authorization denial.
A March 2026 KFF Health News investigation documented a case in which a Florida insurance policy was cancelled because the policyholder owed a balance of five cents — resulting in thousands of dollars of uncovered medical bills. The mechanism was automated: a small outstanding balance triggered cancellation before anyone could catch it.
For fertility patients in the middle of a cycle, this kind of disruption is catastrophic. A frozen embryo transfer can cost $4K–$6K out of pocket without coverage. But a cancelled retrieval cycle — or worse, losing insurance coverage during the luteal phase of a stimulation cycle — can mean the entire $15K–$20K medication and monitoring investment is wasted.
This is not hypothetical. Insurance gaps during fertility treatment are a known risk, especially given the patchwork of state mandates, ERISA loopholes, and employer benefit changes that govern coverage. We cover exactly where those gaps are in IVF Insurance Coverage in 2026: How Medicaid Cuts, ERISA Gaps, and Hospital Consolidation Could Add $15K to Your Fertility Bill.
Before your next cycle, confirm: Is your coverage active through the expected transfer date? Has your employer changed plans? Does your plan require prior authorization for monitoring visits, not just the retrieval itself?
The Financial Pressure Context: Why Timing Matters More Than Ever in 2026
Mortgage rates hit a 2026 high of 6.45% this week. That matters to fertility patients not because you're buying a house, but because the broader financial environment is stretching household budgets in ways that make a $28K–$84K fertility spend harder to absorb.
The families we're talking about are often the same ones weighing a down payment against another IVF cycle. Understanding your cumulative success probability — and honestly evaluating whether a second or third cycle improves your odds meaningfully — is not pessimism. It's the math that lets you make a real decision rather than hoping the next cycle is the lucky one.
If you're deciding between clinics based on a $10K+ price gap, the question isn't just "which clinic is cheaper." It's whether the higher-cost clinic's published success rate, adjusted for your age and diagnosis, is genuinely better — or whether they're selecting for easier cases and inflating their headline number. That's a solvable problem if you have the right data.
What to Do With All of This Before Your Next Appointment
Before you commit to a next cycle — whether it's your first or your third — here are four specific questions to bring to your clinic:
- What is your live birth rate per intended retrieval (not per transfer) for patients my age?
- What percentage of your retrievals are cancelled before reaching a fresh or frozen transfer?
- How does your PGT-A utilization rate affect your reported success stats — are euploid-only transfers included in your denominator?
- What is your protocol for poor responders, and how do those patients affect your published outcomes?
Clinics that can answer these questions clearly are the ones worth your $28K. Clinics that redirect you to a brochure success rate are telling you something important about how they treat data — and by extension, how they'll treat you when your situation gets complicated.
The cumulative math across age brackets, the insurance stability question, and the clinic-level data all come together in one place. Feralyx exists specifically to run this analysis for your personal inputs — age, diagnosis, clinic options, insurance status, and number of cycles you're planning — so that the next $28K you spend is the most informed $28K in the process.
Sources
- Inside the High-Stakes Corporate Fight Over Feeding Preterm Babies — KFF Reproductive Health
- Tech nonprofit sues CMS over Medicare AI prior authorization pilot — Healthcare Dive
- Mortgage Rates Today, Monday, March 30: Record High for 2026 — NerdWallet Health
- She Owed Her Insurer a Nickel, So It Canceled Her Coverage — KFF Reproductive Health
- Duke Health names familiar face as new CEO — Healthcare Dive